Mydecine Innovations Group (STU:0NF0) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mydecine Innovations Group Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Mydecine Innovations Group's net issuance of preferred for the three months ended in Sep. 2023 was €0.00 Mil. The number is 0, which means that Mydecine Innovations Group has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Mydecine Innovations Group's net issuance of preferred for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Mydecine Innovations Group Net Issuance of Preferred Stock Historical Data

The historical data trend for Mydecine Innovations Group's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Net Issuance of Preferred Stock Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Mydecine Innovations Group Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Mydecine Innovations Group Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Mydecine Innovations Group (STU:0NF0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (STU:0NF0) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

MYCOF:USA MYIG:UK MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (STU:0NF0) Headlines

No Headlines